Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study
Authors' conclusion
SGLT2 inhibitors were associated with a reduced risk of adverse cardiorenal outcomes and all-cause mortality and were safely used in patients with DEP.
Study context
- Population
- Individuals with diabetes secondary to disorders of the exocrine pancreas (DEP) initiating glucose-lowering drugs, September 2014–December 2022, Korean National Health Insurance Service database
- Participants
- 66,120 individuals4,128 matched pairs
- Exposure
- SGLT2i vs other glucose-lowering drugs (GLDs)
- SGLT2 inhibitorsn = 4,128
- Other GLDsn = 4,128reference
- Outcome
- Effectiveness outcomes: MACE, HF, end-stage kidney disease (ESKD) and all-cause mortality
- Follow-up
- Mean 2.3 years
Methodological detailsnationwide population-based, propensity-score matched 1:1
- Nationwide population-based
- Propensity-score matched 1:1
Main finding
As reported in the abstract
Effectiveness outcomes
SGLT2i vs Other GLDsHazard ratio (95% CI)
MACE
0.69(0.51–0.93)
Hospitalization for HF
0.70(0.51–0.95)
ESKD
0.19(0.06–0.61)
All-cause mortality
0.38(0.27–0.53)
Observational data: associations, not effects.
Safety
| Outcome | HR (95% CI) | |
|---|---|---|
| Safety outcomes: urinary tract infections and pancreatitisSGLT2ivs Other GLDsUrinary tract infections | 0.87 (0.78–0.96) | |
| Safety outcomes: urinary tract infections and pancreatitisSGLT2ivs Other GLDsPancreatitis | 0.71 (0.58–0.87) | |
| 0.512Hazard ratio (log scale) |
Original publication
Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study. Diabetes Metab. Published 30 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →